The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Open accessAbstract
BACKGROUND: The efficacy and safety of oral ulipristal acetate for the treatment of symptomatic uterine fibroids before surgery are uncertain. METHODS: We randomly assigned women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on the pictorial blood-loss assessment chart [PBAC, an objective assessment of blood loss, in which monthly scores range from 0 to >500, with higher numbers indicating more bleeding]) and anemia (hemoglobin level of ≤10.2 g per deciliter) to receive treatment for up to 13 weeks with oral ulipristal acetate at a dose of 5 mg per day (96 women) or 10 mg per day (98 women) or to receive placebo (48 women). All patients received iron supplementation. The coprimary efficacy end points were control of uterine bleeding (PBAC score of <75) and reduction of fibroid volume at week 13, after which patients could undergo surgery. RESULTS: At 13 weeks, uterine bleeding was controlled in 91% of the women receiving 5 mg of ulipristal acetate, 92% of those receiving 10 mg of ulipristal acetate, and 19% of those receiving placebo (P<0.001 for the comparison of each dose of ulipristal acetate with placebo). The rates of amenorrhea were 73%, 82%, and 6%, respectively, with amenorrhea occurring within 10 days in the majority of patients receiving ulipristal acetate. The median changes in total fibroid volume were -21%, -12%, and +3% (P=0.002 for the comparison of 5 mg of ulipristal acetate with placebo, and P=0.006 for the comparison of 10 mg of ulipristal acetate with placebo). Ulipristal acetate induced benign histologic endometrial changes that had resolved by 6 months after the end of therapy. Serious adverse events occurred in one patient during treatment with 10 mg of ulipristal acetate (uterine hemorrhage) and in one patient during receipt of placebo (fibroid protruding through the cervix). Headache and breast tenderness were the most common adverse events associated with ulipristal acetate but did not occur significantly more frequently than with placebo. CONCLUSIONS: Treatment with ulipristal acetate for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids. (Funded by PregLem; ClinicalTrials.gov number, NCT00755755.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,090
The short-form McGill pain questionnaire
Melzack, R. (1987) · Pain · doi:10.1016/0304-3959(87)91074-8 · Cited by 4,368
Nonparametric Statistical Methods.
Knott, M., Hollander, M., & Wolfe, D. A. (1974) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344557 · Cited by 2,662
Hematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851
Assessment of menstrual blood loss using a pictorial chart
HIGHAM, J. M., O'BRIEN, P. M. S., & SHAW, R. W. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb16249.x · Cited by 1,116
Uterine Myomas: An Overview of Development, Clinical Features, and Management
Wallach, E. E., & Vlahos, N. F. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000136079.62513.39 · Cited by 540
Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids
Lethaby, A., Vollenhoven, B., & Sowter, M. C. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000547 · Cited by 356
Fibroids and female reproduction: a critical analysis of the evidence
Somigliana, E., Vercellini, P., Daguati, R., Pasin, R., De Giorgi, O., & Crosignani, P. G. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm013 · Cited by 351
What are the implications of myomas on fertility?
Donnez, J., & Jadoul, P. (2002) · Human Reproduction · doi:10.1093/humrep/17.6.1424 · Cited by 350
Self-citationChabbert-Buffet, N., Meduri, G., Bouchard, P., & Spitz, I. M. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi002 · Cited by 310
Self-citationThe spectrum of endometrial pathology induced by progesterone receptor modulators
Mutter, G. L., Bergeron, C., Deligdisch, L., Ferenczy, A., Glant, M., Merino, M., Williams, A. R. W., & Blithe, D. L. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.19 · Cited by 236
Racial and ethnic disparities in benign gynecologic conditions and associated surgeries
Jacoby, V. L., Fujimoto, V. Y., Giudice, L. C., Kuppermann, M., & Washington, A. E. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.02.039 · Cited by 213
Marret, H., Fauconnier, A., Chabbert-Buffet, N., Cravello, L., Golfier, F., Gondry, J., Agostini, A., Bazot, M., Brailly-Tabard, S., Brun, J.-L., et al. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.07.016 · Cited by 192
The role of progesterone signaling in the pathogenesis of uterine leiomyoma
Kim, J. J., & Sefton, E. C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.05.044 · Cited by 192
Carr, B. R. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.5.1217 · Cited by 184
Nisolle, M., Gillerot, S., Casanas-Roux, F., Squifflet, J., Berliere, M., & Donnez, J. (1999) · Human Reproduction · doi:10.1093/humrep/14.11.2844 · Cited by 159
Self-citationCDB-2914 for Uterine Leiomyomata Treatment
Levens, E. D., Potlog‐Nahari, C., Armstrong, A. Y., WESLEY, R. A., Premkumar, A., Blithe, D., Blocker, W., & Nieman, L. K. (2008) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181705d0e · Cited by 156
Uterine fibroid tumors: diagnosis and treatment.
Evans, P., & Brunsell, S. (2007) · PubMed · Cited by 152
Progesterone antagonists and progesterone receptor modulators: an overview
Spitz, I. M. (2003) · Steroids · doi:10.1016/j.steroids.2003.08.007 · Cited by 144
Chabbert‐Buffet, N., Pintiaux, A., & Bouchard, P. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2816 · Cited by 138
Self-citationIntrauterine device use among women with uterine fibroids: a systematic review
Zapata, L. B., Whiteman, M. K., Tepper, N. K., Jamieson, D. J., Marchbanks, P. A., & Curtis, K. M. (2010) · Contraception · doi:10.1016/j.contraception.2010.02.011 · Cited by 126
Nieman, L. K., Blocker, W., Nansel, T. R., Mahoney, S. F., Reynolds, J. C., Blithe, D., WESLEY, R. A., & Armstrong, A. Y. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.09.059 · Cited by 123
Attardi, B. J., Burgenson, J., Hild, S. A., Reel, J. R., & Blye, R. P. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00743-2 · Cited by 118
Campo, S. (1999) · Human Reproduction · doi:10.1093/humrep/14.1.44 · Cited by 111
Donnez, J., Schrurs, B., Gillerot, S., Sandow, J., & Clerckx, F. (1989) · Fertility and Sterility · doi:10.1016/s0015-0282(16)60723-9 · Cited by 106
Self-citationMATTA, W. H. M., Shaw, R. W., & NYE, M. (1989) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1989.tb01663.x · Cited by 104
Management of uterine fibroids: an update of the evidence.
Viswanathan, M., Hartmann, K. E., McKoy, N. J., Stuart, G. S., Rankins, N. C., Thieda, P., Lux, L. J., & Lohr, K. N. (2007) · PubMed · Cited by 103
Yin, P., Lin, Z., Reierstad, S., Wu, J., Ishikawa, H., Marsh, E. E., Innes, J. E., Cheng, Y.-H., Pearson, K., Coon, J. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2612 · Cited by 89
Management of patients receiving long-term treatment with mifepristone
Spitz, I. M., Grunberg, S. M., Chabbert‐Buffet, N., Lindenberg, T., Gelber, H., & Sitruk-Ware, R. L. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.05.056 · Cited by 63
The ESHRE Capri Workshop Group (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm001 · Cited by 59
A 41-Year-Old Woman With Menorrhagia, Anemia, and Fibroids
Voorhis, B. J. V. (2008) · JAMA · doi:10.1001/jama.2008.791 · Cited by 46
Scialli, A. R., & Jestila, K. J. (1995) · Fertility and Sterility · doi:10.1016/s0015-0282(16)57729-2 · Cited by 35
Cited by
Uterine fibroid management: From the present to the future
Donnez, J., & Dolmans, M.-M. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw023 · Cited by 780
Self-citationBulun, S. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1209993 · Cited by 703
Epidemiology and management of uterine fibroids
Giuliani, E., As‐Sanie, S., & Marsh, E. E. (2020) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13102 · Cited by 674
The Management of Uterine Leiomyomas
Vilos, G. A., Allaire, C., Laberge, P.-Y., Leyland, N., Vilos, A. G., Murji, A., & Chen, I. (2015) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30338-8 · Cited by 642
Stewart, E. A., Laughlin-Tommaso, S. K., Catherino, W. H., Lalitkumar, S., Gupta, D., & Vollenhoven, B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.43 · Cited by 531
Metadata
- Authors
- Donnez, J., Tatarchuk, T. F., Bouchard, P., Puscasiu, L., Zakharenko, N. F., Ivanova, T., Ugocsai, G., Mara, M., Jilla, M. P., Bestel, E., Terrill, P., Osterloh, I., & Loumaye, E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-02-02
- Volume
- 366
- Issue
- 5
- Pages
- 409-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2106587450
- Cited by
- 680
- References
- 33
- FWCI
- 71.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.